Le Lézard
Classified in: Health, Science and technology
Subject: FDA

FDA Authorizes First Robotically-Assisted Surgical Device for Performing Transvaginal Hysterectomy


SILVER SPRING, Md., March 1, 2021 /PRNewswire/ -- The U.S. Food and Drug Administration has authorized marketing of the Hominis Surgical System, a new robotically-assisted surgical device (RASD) that can help facilitate transvaginal hysterectomy in certain patients. The Hominis Surgical System is intended for benign hysterectomy (removal of the uterus for non-cancerous conditions) with salpingo-oophorectomy (removal of one or both fallopian tubes and ovaries).

"We are providing physicians and patients another minimally-invasive gynecologic surgical option for non-cancerous conditions," said Binita Ashar, M.D., MBA, FACS, director of the Office of Surgical and Infection Control Devices in the FDA's Center for Devices and Radiological Health. "The FDA continues to support advancements in safe and effective medical devices that can improve patient experiences when undergoing surgical procedures."

RASD, sometimes referred to as robotic surgical devices or computer-assisted surgical devices, are not actually robots. The devices cannot perform surgery without direct human control. RASD enable a surgeon to use computer and software technology to control and move surgical instruments through one or more tiny ports (incisions or orifices) in the patient's body and in a variety of surgical procedures or operations. RASD technology facilitates performing minimally-invasive surgery and complex tasks in confined areas inside the body.

To remove the uterus, the Hominis Surgical System uses minimally-invasive surgical instruments inserted through the vagina (transvaginal approach) and a video camera inserted laparoscopically through a small incision on the abdomen for visualization of the instruments inside the patient. The transvaginal approach requires fewer incisions on the abdomen compared to conventional laparoscopic hysterectomy. During the procedure, surgeons in the operating room control the instruments from the Hominis Surgical System console. The FDA will require the manufacturer to develop and provide a comprehensive training program for surgeons and operating room staff to complete before operation of the device.

In addition to its assessment of performance and engineering testing, the FDA evaluated safety and effectiveness in a clinical study of 30 patients undergoing transvaginal total hysterectomy with salpingo-oophorectomy or salpingectomy for benign conditions, using the Hominis Surgical System. Patients had varying characteristics such as ages ranging from 37 to 79 years, body mass index from 17.6?40, and 63% of patients had different comorbidities, such as high cholesterol, osteoporosis or high blood pressure. All 30 procedures with the Hominis Surgical System were successfully completed and there were no conversions to an open or other laparoscopic surgical approach. Observed adverse events included minor blood loss, urinary tract infection and delayed healing of the closure made at the top of the vagina (vaginal cuff) that is done as part of a hysterectomy.    

The FDA reviewed the device through the De Novo premarket review pathway, a regulatory pathway for low- to moderate-risk devices of a new type. Along with this authorization, the FDA is establishing special controls for devices of this type, including requirements related to labeling and performance testing. When met, the special controls, along with general controls, provide reasonable assurance of safety and effectiveness for devices of this type.

The FDA granted marketing authorization of the Hominis Surgical System to Memic Innovative Surgery Ltd.

Additional Resources:

Media Contact: Shirley Simson, 202-597-4230
Consumer Inquiries: Email or 888-INFO-FDA

The FDA, an agency within the U.S. Department of Health and Human Services, protects the public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines, and other biological products for human use, and medical devices. The agency also is responsible for the safety and security of our nation's food supply, cosmetics, dietary supplements, products that give off electronic radiation, and for regulating tobacco products.

 

U.S. Food and Drug Administration (FDA) logo (PRNewsfoto/FDA)

 

SOURCE U.S. Food and Drug Administration


These press releases may also interest you

at 12:05
Workspot, the Enterprise VDI platform built for the multi-cloud and hybrid era, announced today that it has appointed Brad Tompkins as Chief Executive Officer (CEO), effective immediately. Tompkins previously served as the company's President and...

at 12:05
NEC X, the Silicon Valley-based innovation accelerator and venture studio backed by global IT leader NEC, today unveiled the standout startups selected to join Elev X! Ignite cohort Batch 11. The seven new startups were handpicked from more than 250...

at 12:05
VirtualHealth is excited to share that its HELIOS platform was named the winner of a Bronze Stevie® Award in the Healthcare Technology Solution category in The 22nd Annual American Business Awards® today. More than 3,700 nominations were submitted...

at 12:00
Today, eBay is launching its 5th annual Up & Running Grants program ? a series of annual grants that reward 50 U.S. eBay sellers with tools and resources to grow their small businesses. In addition to a $10,000 reward, eBay is offering recipients a...

at 12:00
Immutable, the leading web3 gaming platform and ecosystem, today announced the launch of 'The Main Quest', the largest ever web3 gaming quest and rewards program. With up to $US50M in token rewards already secured for players and more to be...

at 12:00
Moso, the groundbreaking shop-to-earn platform that seamlessly merges online shopping with cryptocurrency, proudly announces the successful completion of its $2 million seed funding round. This achievement marks a pivotal moment in Moso's journey,...



News published on and distributed by: